2016 California Proposition 56

The Oncology Institute Reports Third Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance

Retrieved on: 
Wednesday, November 8, 2023
Growth, Eastern Time Zone, FFS, Michigan House of Representatives, IV, EBITDA, Acquisition, Prescription, Date, Webcast, 2016 California Proposition 56, Clothing, Pharmaceutical industry

Third Quarter 2023 Results (for the three months ended September 30, 2023)

Key Points: 
  • Third Quarter 2023 Results (for the three months ended September 30, 2023)
    Consolidated revenue for Q3 2023 was $82.0 million, an increase of 26.3% compared to Q3 2022, and a 2.3% increase compared to Q2 2023.
  • Revenue for patient services the nine months ended 2023 was $157.3 million, up 32.4% compared to the nine months ended 2022.
  • Gross profit in the nine months ended 2023 was $45.2 million, an increase of 23.9% compared to the nine months ended 2022.
  • TOI will host a conference call and webcast on Wednesday, November 8, 2023 at 5:00 p.m. (Eastern Time) to discuss third quarter results.

The Oncology Institute Reports Second Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance

Retrieved on: 
Tuesday, August 8, 2023
Growth, Earnout, 2016 California Proposition 56, Webcast, Michigan House of Representatives, FFS, Prescription, IV, EBITDA, Eastern Time Zone, Clothing, Pharmaceutical industry

Second Quarter 2023 Results (for the three months ended June 30, 2023)

Key Points: 
  • Second Quarter 2023 Results (for the three months ended June 30, 2023)
    Consolidated revenue for Q2 2023 was $80 million, an increase of 31.7% compared to Q2 2022, and a 5.3% increase compared to Q1 2023.
  • Gross profit in Q2 2023 was $15 million, an increase of 35.7% compared to Q2 2022.
  • During the first half of 2023, share-based compensation expense was $9 million compared to $15 million for the same period of 2022.
  • TOI will host a conference call and webcast on Tuesday, August 8, 2023 at 5:00 p.m. (Eastern Time) to discuss second quarter results.

The Oncology Institute Reports First Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance

Retrieved on: 
Wednesday, May 10, 2023
Growth, Earnout, 2016 California Proposition 56, Michigan House of Representatives, FFS, Prescription, IV, EBITDA, Investment, Eastern Time Zone, Pharmaceutical industry

TOI's outlook assumes a largely reopened global market, which would be negatively impacted if closures or other restrictive measures persist or are reimplemented.

Key Points: 
  • TOI's outlook assumes a largely reopened global market, which would be negatively impacted if closures or other restrictive measures persist or are reimplemented.
  • Consolidated revenue for Q1 2023 was $76 million, an increase of 38.1% compared to Q1 2022, and a 6.7% increase compared to Q4 2022.
  • Gross profit in Q1 2023 was $14 million, an increase of 14.4% compared to Q1 2022.
  • TOI will host a conference call on Wednesday, May 10, 2023 at 5:00 p.m. (Eastern Time) to discuss first quarter results and management’s outlook for future financial and operational performance.

CORRECTION -- The Oncology Institute Reports Updated Fourth Quarter and Full Year 2022 Financial Results and Guidance for 2023

Retrieved on: 
Friday, March 17, 2023
Michigan House of Representatives, IV, SG, 2016 California Proposition 56, Prescription, EBITDA, Growth, Earnout, FFS, Cryptocurrency, Pharmaceutical industry

TOI's achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in its filings with the U.S. Securities and Exchange Commission.

Key Points: 
  • TOI's achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in its filings with the U.S. Securities and Exchange Commission.
  • Consolidated revenue for Q4 2022 was $71 million, an increase of 36.6% compared to Q4 2021, and a 9.9% increase compared to Q3 2022.
  • Revenue for patient services was $48 million, up 51.4% compared to Q4 2021.
  • Gross profit in Q4 2022 was $16 million, an increase of 87.6% compared to Q4 2021.

The Oncology Institute Reports Fourth Quarter and Full Year 2022 Financial Results and Guidance for 2023

Retrieved on: 
Thursday, March 9, 2023
2016 California Proposition 56, Earnout, Eastern Time Zone, Growth, FFS, EBITDA, SG, IV, Michigan House of Representatives, Prescription, Cryptocurrency, Pharmaceutical industry

TOI's achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in its filings with the U.S. Securities and Exchange Commission.

Key Points: 
  • TOI's achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in its filings with the U.S. Securities and Exchange Commission.
  • Consolidated revenue for Q4 2022 was $71 million, an increase of 36.6% compared to Q4 2021, and a 9.9% increase compared to Q3 2022.
  • Gross profit in Q4 2022 was $16 million, an increase of 87.6% compared to Q4 2021.
  • TOI will host a conference call on Thursday, March 9, 2023 at 5:00 p.m. (Eastern Time) to discuss fourth quarter and full year results and management’s outlook for future financial and operational performance.